spacer
home > ebr > winter 2003 > in conversation with mary harney
PUBLICATIONS
European Biopharmaceutical Review

In conversation with Mary Harney

Mary Harney is the Irish Deputy Prime Minister and Minister for Enterprise Trade and Employment. She has had a direct hand in driving Ireland's recent impressive science research foundation programmes, identified as critical if Ireland was to underpin an emerging biotechnology industry on the back of decades of inward investment in pharmaceutical manufacturing expertise. A Tainiste, to give Mrs Harney her true political title in Ireland, is equally outspoken on the importance of knowledge-based industry - and biotechnology in particular - to future European economic growth along with the need for political will to replace rhetoric at the highest level. As incoming President of the EU Competitiveness Council, which oversees the EU's life sciences biotechnology strategy, Mrs Harney represented the most relevant and senior of political commentators to bring the political message at the Opening Plenary session of the CORDIA-EuropaBio Convention in December 2003.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Ireland Makes its Mark in Europe in the Opening Session of the Inaugural CORDIA-EuropaBio Convention, Vienna, December 2003

By Dr Helen Abbott, Chair Editorial Board of EBR and Member of Executive Steering Group, CORDIA-EuropaBio Convention 2003

spacer
Mary Harney
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement